Surg Oncol Clin Pract J | Volume 3, Issue 1 | Case Report | Open Access

A Rare Case of Peritoneal Mesothelioma with Complete Pathological Response after Treatment with Pemetrexed/Cisplatin and Cytoreductive Surgery with HIPEC

Colin J Rog, Shelby Reiter, Evan S Ong and Mohamed Alassas*

Department of General Surgery, Division of Surgical Oncology, Swedish Medical Center, USA

*Correspondance to: Mohamed Alassas 

Fulltext PDF


Malignant  peritoneal  mesothelioma  is  a  rare  malignancy  with  a  generally  poor  prognosis. For  patients  with  resectable  disease,  cytoreductive  surgery  with  hyperthermic  intraperitoneal chemotherapy  offers  the  best  chance  of  overall  survival.  However,  in  patients  with  initially unresectable  disease,  chemotherapy  with  pemetrexed  and  cisplatin  remains  the  only  treatment option.  In  some  cases,  up-front  chemotherapy  will  enhance  a  patient’s  resectability,  making  the patient a surgical candidate. Complete pathological response is an extremely rare outcome with only a handful of cases reported in recent literature. We report a case of a 44-year-old male patient with initially unresectable malignant peritoneal mesothelioma who received pemetrexed and cisplatin with good response and then underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, demonstrating complete pathologic response on final pathology. This is a rare case that may provide helpful insight into the successful treatment of initially unresectable malignant peritoneal mesothelioma.




Rog CJ, Reiter S, Ong ES, Alassas M. A  Rare Case of Peritoneal Mesothelioma with Complete Pathological Response 
after Treatment with Pemetrexed/Cisplatin and Cytoreductive Surgery with HIPEC. Surg Oncol Clin Pract J. 2020;3(1):1013..

Subscribe to Our Newsletter